Evidence map›Paper›PMID 40661613›Full record

ArticlebioRxiv : the preprint server for biology2025

RetiGene, a comprehensive gene atlas for inherited retinal diseases (IRDs).

Mathieu Quinodoz, Elifnaz Celik, Dhryata Kamdar, Francesca Cancellieri, Karolina Kaminska, Mukhtar Ullah, Pilar Barberán-Martínez, Manon Bouckaert, Marta Cortón, Emma Delanote and 21 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Mathieu QuinodozOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.
Elifnaz CelikOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.
Dhryata KamdarOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.
Francesca CancellieriOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.
Karolina KaminskaOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.
Mukhtar UllahOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.
Pilar Barberán-MartínezMolecular, Cellular, and Genomic Biomedicine Group, IIS-La Fe, Valencia, 46012, Spain.
Manon BouckaertCenter for Medical Genetics Ghent, Ghent University, Ghent, 9000, Belgium.
Marta CortónDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, 28040, Spain.
Emma DelanoteCenter for Medical Genetics Ghent, Ghent University, Ghent, 9000, Belgium.
Lidia Fernández-CaballeroDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, 28040, Spain.
Gema García GarcíaMolecular, Cellular, and Genomic Biomedicine Group, IIS-La Fe, Valencia, 46026, Spain.
Lara K HoltesDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Marianthi KaraliMedical Genetics, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, 80138, Italy.
Irma LopezMcGill Ocular Genetics Laboratory and Centre, Department of Paediatric Surgery, Human Genetics, and Ophthalmology, McGill University, Montreal, Canada.
Virginie G PeterOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.
Nina SchneiderHadassah Medical Center, Department of Ophthalmology, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel.
Lieselot VinckeCenter for Medical Genetics Ghent, Ghent University, Ghent, 9000, Belgium.
Carmen AyusoDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, 28040, Spain.
Sandro BanfiMedical Genetics, Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, 80138, Italy.
Beatrice BocquetInstitute for Neurosciences of Montpellier, Université de Montpellier, Montpellier, 34091, France.
Frauke CoppietersCenter for Medical Genetics Ghent, Ghent University, Ghent, 9000, Belgium.
Frans P M CremersDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Chris F InglehearnDivision of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK.ORCID 0000-0002-5143-2562
Takeshi IwataDivision of Molecular and Cellular Biology, National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan.
Vasiliki KalatzisInstitute for Neurosciences of Montpellier, Université de Montpellier, Montpellier, 34091, France.
Robert K KoenekoopDepartment of Paediatric Surgery, Human Genetics, and Ophthalmology, Montreal Children's Hospital, McGill University and McGill University Health Center Research Institute, Montreal, H4A 3S5, Canada.
José M MillánMolecular, Cellular, and Genomic Biomedicine Group, IIS-La Fe, Valencia, 46026, Spain.
Dror SharonHadassah Medical Center, Department of Ophthalmology, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel.
Carmel ToomesDivision of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK.
Carlo RivoltaOphthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland.ORCID 0000-0002-0733-9950

Funding

NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with retinitis pigmentosaUG1EY033293 · NEI · JOHNS HOPKINS UNIVERSITY · PI Xiangrong Kong · 2022 to 2026
$18.1M
Antisense therapy for the treatment of visual loss in Usher syndromeR01EY030499 · NEI · LSU HEALTH SCIENCES CENTER · PI KOENEKOOP, ROBERT, LENTZ, JENNIFER JEAN · 2019 to 2023
$1.7M
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis PigmentosaUG1EY033286 · NEI · JOHNS HOPKINS UNIVERSITY · PI Peter A Campochiaro · 2022 to 2026
$1.7M
NAC Attack AOSLO Reading CenterUG1EY033292 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph Carroll, JACQUE LYNNE DUNCAN · 2022 to 2026
$915k
NEI NIH HHS R01 EY030499NEI NIH HHS UG1 EY033286NEI NIH HHS UG1 EY033292NEI NIH HHS UG1 EY033293
6 · The paper itself

Abstract

Inherited retinal diseases (IRDs) are rare disorders, typically presenting as Mendelian traits, that result in stationary or progressive visual impairment. They are characterized by extensive genetic heterogeneity, possibly the highest among all human genetic diseases, as well as diverse inheritance patterns. Despite advances in gene discovery, limited understanding of gene function and challenges in accurately interpreting variants continue to hinder both molecular diagnosis and genetic research in IRDs. One key problem is the absence of a comprehensive and widely accepted catalogue of disease genes, which would ensure consistent genetic testing and reliable molecular diagnoses. With the rapid pace of IRD gene discovery, gene catalogues require frequent validation and updates to remain clinically and scientifically useful. To address these gaps, we developed RetiGene, an expert-curated gene atlas that integrates variant data, bulk and single-cell RNA sequencing, and functional annotations. Through the integration of diverse data sources, RetiGene supports candidate gene prioritization, functional studies, and therapeutic development in IRDs.

Identifiers

PMID40661613
PMCPMC12259000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.